Bristol Myers Squibb Revenue 2010-2022 | BMY

Bristol Myers Squibb annual/quarterly revenue history and growth rate from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Bristol Myers Squibb revenue for the quarter ending September 30, 2022 was $11.218B, a 3.49% decline year-over-year.
  • Bristol Myers Squibb revenue for the twelve months ending September 30, 2022 was $46.738B, a 2.79% increase year-over-year.
  • Bristol Myers Squibb annual revenue for 2021 was $46.385B, a 9.09% increase from 2020.
  • Bristol Myers Squibb annual revenue for 2020 was $42.518B, a 62.62% increase from 2019.
  • Bristol Myers Squibb annual revenue for 2019 was $26.145B, a 15.89% increase from 2018.
Bristol Myers Squibb Annual Revenue
(Millions of US $)
2021 $46,385
2020 $42,518
2019 $26,145
2018 $22,561
2017 $20,776
2016 $19,427
2015 $16,560
2014 $15,879
2013 $16,385
2012 $17,621
2011 $21,244
2010 $19,484
2009 $18,808
Bristol Myers Squibb Quarterly Revenue
(Millions of US $)
2022-09-30 $11,218
2022-06-30 $11,887
2022-03-31 $11,648
2021-12-31 $11,985
2021-09-30 $11,624
2021-06-30 $11,703
2021-03-31 $11,073
2020-12-31 $11,068
2020-09-30 $10,540
2020-06-30 $10,129
2020-03-31 $10,781
2019-12-31 $7,945
2019-09-30 $6,007
2019-06-30 $6,273
2019-03-31 $5,920
2018-12-31 $5,973
2018-09-30 $5,691
2018-06-30 $5,704
2018-03-31 $5,193
2017-12-31 $5,449
2017-09-30 $5,254
2017-06-30 $5,144
2017-03-31 $4,929
2016-12-31 $5,243
2016-09-30 $4,922
2016-06-30 $4,871
2016-03-31 $4,391
2015-12-31 $4,287
2015-09-30 $4,069
2015-06-30 $4,163
2015-03-31 $4,041
2014-12-31 $4,258
2014-09-30 $3,921
2014-06-30 $3,889
2014-03-31 $3,811
2013-12-31 $4,441
2013-09-30 $4,065
2013-06-30 $4,048
2013-03-31 $3,831
2012-12-31 $4,191
2012-09-30 $3,736
2012-06-30 $4,443
2012-03-31 $5,251
2011-12-31 $5,454
2011-09-30 $5,345
2011-06-30 $5,434
2011-03-31 $5,011
2010-12-31 $5,111
2010-09-30 $4,798
2010-06-30 $4,768
2010-03-31 $4,807
2009-12-31 $5,033
2009-09-30 $4,788
2009-06-30 $4,665
2009-03-31 $4,322
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $168.477B $46.385B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
GSK (GSK) United Kingdom $69.125B 8.67
Bio-Rad Laboratories (BIO.B) United States $11.666B 27.68
QIAGEN (QGEN) Netherlands $11.120B 18.98
Ginkgo Bioworks Holdings (DNA) United States $3.861B 0.00
Myovant Sciences (MYOV) United Kingdom $2.592B 0.00
Arcus Biosciences (RCUS) United States $1.934B 29.03
Biohaven (BHVN) United States $1.080B 0.00
Emergent Biosolutions (EBS) United States $0.594B 4.67
Zymeworks (ZYME) Canada $0.494B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.276B 0.00
Enzo Biochem (ENZ) United States $0.095B 0.00
SQZ Biotechnologies (SQZ) United States $0.078B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00